Engineered single chain antibody fragments for radioimmunotherapy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 4, 2004, Pages 279-288

  Huhalov, A ^a   Chester, K A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Affinity; Avidity; Immunogenicity; Pharmacokinetics; Radioimmunotherapy; Recombinant; Single chian Fv

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY A5B7; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY I 125; IMMUNOGLOBULIN G I 125; LYMPHOCYTE ANTIBODY; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY CC49 I 123; MONOCLONAL ANTIBODY I 123; MONOCLONAL ANTIBODY I 125; MONOCLONAL ANTIBODY TC 99; PROTEIN P53 TC 99; RADIOPHARMACEUTICAL AGENT; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTAVIDIN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN FV;

ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CARCINOMA; DNA CROSS LINKING; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TARGETING; GENETIC ENGINEERING; HUMAN; IMAGE ANALYSIS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; IN VITRO SELECTION; ISOTOPE LABELING; NONHUMAN; POLYMERASE CHAIN REACTION; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; RADIOSURGERY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; ANIMAL; ANTIBODY PRODUCTION; ARTICLE; BIOSYNTHESIS; DRUG DESIGN; GENETICS; METABOLISM; METHODOLOGY; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; DRUG DESIGN; HUMANS; IMMUNOGLOBULIN FRAGMENTS; PROTEIN ENGINEERING; RADIOIMMUNOTHERAPY;

EID: 15944388634     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Boehm MK, Corper AL, Wan T, Sohi MK, Sutton BJ, Thornton JD et al. Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J 2000;346 Pt 2:519-28.
2. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A 1988;85:5879-83.
3. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM et al. Single-chain antigen-binding proteins. Science 1988;242:423-6.
4. Bradbury AR, Marks JD. Antibodies from phage antibody libraries. J Immunol Methods 2004;290:29-49.
5. Lipovsek D, Pluckthun A. In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 2004;290:51-67.
6. Daugherty PS, Chen G, Olsen MJ, Iverson BL, Georgiou G. Antibody affinity maturation using bacterial surface display. Protein Eng 1998;11:825-32.
7. Feldhaus MJ, Siegel RW. Yeast display of antibody fragments: a discovery and characterization platform. J Immunol Methods 2004;290:69-80.
8. Kurtzman AL, Govindarajan S, Vahle K, Jones JT, Heinrichs V, Patten PA. Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins. Curr Opin Biotechnol 2001;12:361-70.
9. Maynard J, Georgiou G. Antibody engineering. Annu Rev Biomed Eng 2000;2:339-76.
10. Worn A, Pluckthun A. Stability engineering of antibody singlechain Fv fragments. J Mol Biol 2001;305:989-1010.
11. Chester KA, Begent RH, Robson L, Keep P, Pedley RB, Boden JA et al. Phage libraries for generation of clinically useful antibodies. Lancet 1994;343:455-6.
12. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81.
13. Graff CP, Chester K, Begent R, Wittrup KD. Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng Des Sel 2004;17:293-304.
14. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990;82:1191-7.
15. Milenic DE, Yokota T, Filpula DR, Finkelman MA, Dodd SW, Wood JF et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363-71.
16. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF III et al. Highly, specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993;53:4026-34.
17. Verhaar MJ, Chester KA, Keep PA, Robson L, Pedley RB, Boden JA et al. A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma. Int J Cancer 1995;61:497-501.
18. Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 1997;80:2591-610.
19. Tsai SW, Li L, Williams LE, Anderson AL, Raubitschek AA, Shively JE. Metabolism and renal clearance of 111In-labeled DOTA-conjugated antibody fragments. Bioconjug Chem 2001;12:264-70.
20. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996;2:979-84.
21. Larson SM, El Shirbiny AM, Divgi CR, Sgouros G, Finn RD, Tschmelitsch J et al. Single chain antigen binding protein (sFv CC49): first human studies in colorectal carcinoma metastatic to liver. Cancer 1997;80:2458-68.
22. Mayer A, Tsiompanou E, O'Malley D, Boxer GM, Bhatia J, Flynn AA et al. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res 2000;6:1711-9.
23. Lane DM, Eagle KF, Begent RH, Hope-Stone LD, Green AJ, Casey JL et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer 1994;70:521-5.
24. Whitlow M, Bell BA, Feng SL, Filpula D, Hardman KD, Hubert SL et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng 1993;6: 989-95.
25. Wu AM, Chen W, Raubitschek A, Williams LE, Neumaier M, Fischer R et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 1996;2: 21-36.
26. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998;77:1405-12.
27. Beresford GW, Pavlinkova G, Booth BJ, Batra SK, Colcher D. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody. Int J Cancer 1999;81:911-7.
28. Pavlinkova G, Beresford GW, Booth BJ, Batra SK, Colcher D. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J Nucl Med 1999;40:1536-46.
29. Nielsen UB, Adams GP, Weiner LM, Marks JD. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res 2000;60: 6434-40.
30. Flynn AA, Pedley RB, Green AJ, Boxer GM, Boden R, Begent RH. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images. Cancer Biother Radiopharm 2001;16:391-400.
31. Willuda J, Kubetzko S, Waibel R, Schubiger PA, Zangemeister-Wittke U, Pluckthun A. Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides. J Biol Chem 2001;276:14385-92.
32. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002; 102:75-85.
33. Yazaki PJ, Wu AM, Tsai SW, Williams LE, Ikler DN, Wong JY et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug Chem 2001;12:220-8.
34. Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJ, Pavlinkova G et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res 2000;60:6964-71.
35. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055-61.
36. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-9.
37. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom. HR, Hudson PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 2001;248: 47-66.
38. Olafsen T, Cheung CW, Yazaki PJ, Li L, Sundaresan G, Gambhir SS et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel 2004;17:21-7.
39. Goel A, Augustine S, Baranowska-Kortylewicz J, Colcher D, Booth BJ, Pavlinkova G et al. Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 1311-labeled multivalent CC49 single-chain fvs. Clin Cancer Res 2001;7:175-84.
40. Huhalov H, Graff C, Wittrup KD, Tolner B, Pedley RB, Vervecken W et al. HSA bodies: a new class of engineered antibody-based molecules for targeting cancer. Br J Cancer 2004;91 Suppl 1: S63-S63.
41. Pluckthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997;3:83-105.
42. Wu AM, Yazaki PJ, Tsai S, Nguyen K, Anderson AL, McCarthy DW et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A 2000;97:8495-500.
43. Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA et al. 124I-abeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962-9.
44. Olafsen T, Tan GJ, Cheung CW, Yazaki PJ, Park JM, Shively JE et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004;17:315-23.
45. Arndt KM, Pelletier JN, Muller KM, Alber T, Michnick SW, Pluckthun A. A heterodimeric coiled-coil peptide pair selected in vivo from a designed library-versus-library ensemble. J Mol Biol 2000;295:627-39.
46. Dubel S, Breitling F, Kontermann R, Schmidt T, Skerra A, Little M. Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv). J Immunol Methods 1995;178:201-9.
47. Schultz J, Lin Y, Sanderson J, Zuo Y, Stone D, Mallett R et al. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res 2000;60:6663-9.
48. Goshorn S, Sanderson J, Axworthy D, Lin Y, Hylarides M, Schultz J. Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy. Cancer Biother Radiopharm 2001;16:109-23.
49. Zhang M, Zhang Z, Garmestani K, Schultz J, Axworthy DB, Goldman CK et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A 2003;100:1891-5.
50. Lewis MR, Zhang J, Jia F, Owen NK, Cutler CS, Embree MF et al. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol 2004; 31:213-23.
51. Cheung NK, Modak S, Lin Y, Guo H, Zanzonico P, Chung J et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med 2004;45:867-77.
52. Clark M. Antibody humanization: a case of the "Emperor's new clothes"? Immunol Today 2000;21:397-402.
53. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-31.
54. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G et al. Fully synthetic human combinatorial antibody libranes (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000;296:57-86.
55. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997;15:146-56.
56. He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J et al. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J Immunol 2002;169:595-605.
57. O'Connell D, Becerril B, Roy-Burman A, Daws M, Marks JD. Phage versus phagemid libraries for generation of human monoclonal anti-bodies. J Mol Biol 2002;321:49-56.
58. Baca M, Presta LG, O'Connor SJ, Wells JA. Antibody humanization using monovalent phage display. J Biol Chem 1997;272:10678-84.
59. Rader C, Cheresh DA, Barbas CF III. A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc Natl Acad Sci U S A 1998; 95:8910-5.
60. Pedersen JT, Henry AH, Searle SJ, Guild BC, Roguska M, Rees AR. Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies. J Mol Biol 1994;235:959-73.
61. Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci U S A 1994; 91: 969-73.
62. Kim IS, Yoo TM, Kobayashi H, Kim MK, Le N, Wang QC et al. Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc. Bioconjug Chem 1999;10:447-53.
63. Kobayashi H, Le N, Kim IS, Kim MK, Pie JE, Drumm D et al. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res 1999;59:422-30.
64. Pavlinkova G, Beresford G, Booth BJ, Batra SK, Colcher D. Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis. Nucl Med Biol 1999;26:27-34.
65. Onda M, Nagata S, Tsutsumi Y, Vincent JJ, Wang Q, Kreitman RJ et al. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res 2001;61: 5070-7.
66. Arano, Y, Wakisaka K, Akizawa H, Ono M, Kawai K, Nakayama M et al. Assessment of the radiochemical design of antibodies with a metabolizable linkage for target-selective radioactivity delivery. Bioconjug Chem 1998;9:497-506.
67. Fujioka Y, Arano Y, Ono M, Uehara T, Ogawa K, Namba S et al. Renal metabolism of 3′-iodohippuryl N(epsilon)-maleoyl-L-lysine (HML)-conjugated Fab fragments. Bioconjug Chem 2001;12:178-85.
68. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Defiv Rev 2002;54:531-45.
69. Yang K, Basu A, Wang M, Chintala R, Hsieh MC, Liu S et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng 2003;16:761-70.
70. East L, Isacke CM. The mannose receptor family. Biochim Biophys Acta 2002;1572:364-86.
71. Medzihradszky KF, Spencer DI, Sharma SK, Bhatia J, Pedley RB, Read DA et al. Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. Glycobiology 2003; 14:27-37.